Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Positive-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Single Suprachoroidal Space Injection of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)

NCT06839339 is registered in ClinicalTrials.gov with Beijing Anlong Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06839339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Positive-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Single Suprachoroidal Space Injection of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)
Lead sponsor
Beijing Anlong Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 18, 2025
Completion date
January 30, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration (wamd)